67 related articles for article (PubMed ID: 22331737)
1. Multiple myeloma with serous membrane involvement and increased CA-125 and CA 15-3.
Gunaldi M; Helvaci A; Demirel Yildirim N; Aydin D; Kara N
J BUON; 2011; 16(4):778. PubMed ID: 22331737
[No Abstract] [Full Text] [Related]
2. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
3. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
Pissaia A; Bernard D; Scatton O; Soubrane O; Conti F; Calmus Y
Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
[TBL] [Abstract][Full Text] [Related]
4. Method comparison for CA 15-3, CA 19-9, and CA 125 determination using the new LOCI technique of Dimension Vista 1500 and Immulite 2000 XPI.
Zur B; Holdenrieder S; Albers E; Walgenbach-Brünagel G; Stoffel-Wagner B
J Immunoassay Immunochem; 2012; 33(4):435-45. PubMed ID: 22963492
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study.
Ercan Ş; Kaymaz Ö; Yücel N; Orçun A
Arch Gynecol Obstet; 2012 Mar; 285(3):579-84. PubMed ID: 21792548
[TBL] [Abstract][Full Text] [Related]
6. Measurement of tumor markers in chronic hemodialysis patients.
Tzitzikos G; Saridi M; Filippopoulou T; Makri A; Goulioti A; Stavropoulos T; Stamatiou K
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):50-3. PubMed ID: 20061692
[TBL] [Abstract][Full Text] [Related]
7. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
[TBL] [Abstract][Full Text] [Related]
8. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
[TBL] [Abstract][Full Text] [Related]
9. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Zhang Z; Barnhill SD; Zhang H; Xu F; Yu Y; Jacobs I; Woolas RP; Berchuck A; Madyastha KR; Bast RC
Gynecol Oncol; 1999 Apr; 73(1):56-61. PubMed ID: 10094881
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
11. Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature.
de Larrea CF; Cibeira MT; Vallansot R; Colomo L; Bladé J
Clin Lymphoma Myeloma; 2008 Oct; 8(5):312-4. PubMed ID: 18854288
[TBL] [Abstract][Full Text] [Related]
12. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
13. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic value of multiple tumor marker detection for mature and immature teratoma of the ovary].
Chen C; Li JD; Huang H; Feng YL; Wang LH; Chen L
Ai Zheng; 2008 Jan; 27(1):92-5. PubMed ID: 18184473
[TBL] [Abstract][Full Text] [Related]
15. The effect of maternal age, parity, and fetal sex on the amniotic fluid and maternal serum levels of CA 125, CA 19.9, CA 15.3, and CEA.
Tayyar M; Tutus A
Int J Fertil Womens Med; 1999; 44(5):256-9. PubMed ID: 10569455
[TBL] [Abstract][Full Text] [Related]
16. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
17. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
[TBL] [Abstract][Full Text] [Related]
18. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
19. CA-125 level preoperative assessment in early and advanced ovarian carcinoma.
Raspollini MR
Gynecol Oncol; 2007 Nov; 107(2):356-7; author reply 357-8. PubMed ID: 17716712
[No Abstract] [Full Text] [Related]
20. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
Oremek G; Sauer-Eppel H; Klepzig M
Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]